[go: up one dir, main page]

IL143301A0 - Micronized eplerenone compositions - Google Patents

Micronized eplerenone compositions

Info

Publication number
IL143301A0
IL143301A0 IL14330199A IL14330199A IL143301A0 IL 143301 A0 IL143301 A0 IL 143301A0 IL 14330199 A IL14330199 A IL 14330199A IL 14330199 A IL14330199 A IL 14330199A IL 143301 A0 IL143301 A0 IL 143301A0
Authority
IL
Israel
Prior art keywords
micronized eplerenone
compositions
eplerenone compositions
micronized
eplerenone
Prior art date
Application number
IL14330199A
Other languages
English (en)
Original Assignee
Searle & Co
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=22339668&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=IL143301(A0) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Searle & Co filed Critical Searle & Co
Publication of IL143301A0 publication Critical patent/IL143301A0/xx

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/4841—Filling excipients; Inactive ingredients
    • A61K9/4866—Organic macromolecular compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
    • A61K31/58—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids containing heterocyclic rings, e.g. danazol, stanozolol, pancuronium or digitogenin
    • A61K31/585—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids containing heterocyclic rings, e.g. danazol, stanozolol, pancuronium or digitogenin containing lactone rings, e.g. oxandrolone, bufalin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0087—Galenical forms not covered by A61K9/02 - A61K9/7023
    • A61K9/0095—Drinks; Beverages; Syrups; Compositions for reconstitution thereof, e.g. powders or tablets to be dispersed in a glass of water; Veterinary drenches
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2013—Organic compounds, e.g. phospholipids, fats
    • A61K9/2018—Sugars, or sugar alcohols, e.g. lactose, mannitol; Derivatives thereof, e.g. polysorbates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2022—Organic macromolecular compounds
    • A61K9/205—Polysaccharides, e.g. alginate, gums; Cyclodextrin
    • A61K9/2054—Cellulose; Cellulose derivatives, e.g. hydroxypropyl methylcellulose
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/4841—Filling excipients; Inactive ingredients
    • A61K9/4858—Organic compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/10—Antioedematous agents; Diuretics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/04—Inotropic agents, i.e. stimulants of cardiac contraction; Drugs for heart failure
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/12—Antihypertensives

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Chemical & Material Sciences (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Organic Chemistry (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Diabetes (AREA)
  • Molecular Biology (AREA)
  • Biophysics (AREA)
  • Endocrinology (AREA)
  • Hospice & Palliative Care (AREA)
  • Vascular Medicine (AREA)
  • Urology & Nephrology (AREA)
  • Hematology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Steroid Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
IL14330199A 1998-12-09 1999-12-08 Micronized eplerenone compositions IL143301A0 (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US11164698P 1998-12-09 1998-12-09
PCT/US1999/029136 WO2000033847A1 (en) 1998-12-09 1999-12-08 Micronized eplerenone compositions

Publications (1)

Publication Number Publication Date
IL143301A0 true IL143301A0 (en) 2002-04-21

Family

ID=22339668

Family Applications (1)

Application Number Title Priority Date Filing Date
IL14330199A IL143301A0 (en) 1998-12-09 1999-12-08 Micronized eplerenone compositions

Country Status (30)

Country Link
US (7) US6410054B1 (is)
EP (1) EP1135139B1 (is)
JP (1) JP2002531508A (is)
KR (1) KR100671275B1 (is)
CN (1) CN1230179C (is)
AR (1) AR028982A1 (is)
AT (1) ATE249223T1 (is)
AU (1) AU763166B2 (is)
BR (1) BR9915964A (is)
CA (1) CA2326842A1 (is)
CZ (1) CZ20011942A3 (is)
DE (1) DE69911240T2 (is)
DK (1) DK1135139T3 (is)
EA (1) EA003266B1 (is)
ES (1) ES2207977T3 (is)
HK (1) HK1041641B (is)
HU (1) HU224428B1 (is)
ID (1) ID30115A (is)
IL (1) IL143301A0 (is)
IS (1) IS2325B (is)
MY (1) MY125651A (is)
NO (1) NO20012782L (is)
NZ (1) NZ511869A (is)
PL (1) PL198425B1 (is)
PT (1) PT1135139E (is)
TR (1) TR200101643T2 (is)
TW (1) TWI234459B (is)
UA (1) UA74141C2 (is)
WO (1) WO2000033847A1 (is)
ZA (1) ZA200104361B (is)

Families Citing this family (94)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
UA74141C2 (uk) * 1998-12-09 2005-11-15 Дж.Д. Сірл Енд Ко. Фармацевтична композиція на основі тонкоподрібненого еплеренону (варіанти), спосіб її одержання та спосіб лікування розладів, опосередкованих альдостероном (варіанти)
EP1527782A1 (en) * 1999-12-08 2005-05-04 Pharmacia Corporation Nanoparticulate eplerenone compositions
PT1175220E (pt) * 1999-12-08 2005-07-29 Pharmacia Corp Composicoes de eplerenona em nanoparticulas
EP1280533A2 (en) * 2000-05-11 2003-02-05 Pharmacia Corporation Aldosterone antagonist composition for release during aldosterone acrophase
EP1368009A2 (en) * 2000-07-27 2003-12-10 Pharmacia Corporation Aldosterone blocker therapy to prevent or treat inflammation-related disorders
US20020123485A1 (en) * 2000-07-27 2002-09-05 Alexander John C. Epoxy steroidal aldosterone antagonist and beta-adrenergic antagonist combination therapy for treatment of congestive heart failure
EP1313485B1 (en) * 2000-08-28 2005-10-12 Pharmacia Corporation Use of an aldosterone receptor antagonist to improve cognitive function
US8168616B1 (en) * 2000-11-17 2012-05-01 Novartis Ag Combination comprising a renin inhibitor and an angiotensin receptor inhibitor for hypertension
JP4021327B2 (ja) 2001-03-12 2007-12-12 インターセプト ファーマスーティカル インコーポレイテッド Ｆｘｒに対する作用薬としてのステロイド
US20040173146A1 (en) * 2001-06-07 2004-09-09 Figueroa Iddys D. Application of a bioactive agent to a delivery substrate
US20040173147A1 (en) * 2001-06-07 2004-09-09 Figueroa Iddys D. Application of a bioactive agent to a delivery substrate
US6962715B2 (en) * 2001-10-24 2005-11-08 Hewlett-Packard Development Company, L.P. Method and dosage form for dispensing a bioactive substance
GB0114532D0 (en) * 2001-06-14 2001-08-08 Jagotec Ag Novel compositions
ATE363917T1 (de) * 2001-07-19 2007-06-15 Pharmacia Corp Kombination von einem aldosterone rezeptor antagonisten und einem hmg coa reduktase hemmer
MXPA04005803A (es) * 2001-12-13 2004-11-01 Pharmacia Corp Metodos para tratamiento o profilaxis de efectos patogenicos mediados por aldosterona en un sujeto utilizando un antagonista de aldosterona epoxi-esteroidal.
CA2473797A1 (en) * 2002-01-30 2003-08-07 Pharmacia Corporation Aldosterone antagonist and non-steroidal anti-inflammatory agent combination therapy to prevent or treat cardiovascular disorders
PL208114B1 (pl) * 2002-02-26 2011-03-31 Astrazeneca Ab Kompozycja farmaceutyczna, sposób jej wytwarzania i zastosowanie
BR0308475A (pt) * 2002-03-20 2005-01-11 Pharmacia Corp Formulação de eplerenona estável na armazenagem
US7235655B2 (en) * 2002-03-22 2007-06-26 Pharmacia & Upjohn Company Processes to prepare eplerenone
HK1079997A1 (zh) * 2002-04-26 2006-04-21 舍林股份公司 治疗接受激素替代疗法之妇女中的高血压的方法
BR0313693A (pt) * 2002-08-23 2007-08-14 Pharmacia Corp modulação de atividade de matriz metaloproteinase (mmp) com bloqueador(es) aldosterona
AU2003279070A1 (en) * 2002-09-30 2004-04-23 Acusphere Inc Sustained release porous microparticles for inhalation
EP1558265B1 (en) * 2002-11-05 2010-01-06 Bayer Schering Pharma Aktiengesellschaft Use of drospirenone for the treatment of hypertension
US7786101B2 (en) * 2002-11-05 2010-08-31 Bayer Schering Pharma Ag Cardiovascular protection using anti-aldosteronic progestins
WO2004041288A1 (en) * 2002-11-05 2004-05-21 Schering Aktiengesellschaft Hormone replacement therapy with drospirenone
WO2004054549A1 (en) * 2002-12-13 2004-07-01 Jagotec Ag A topical nanoparticulate spironolactone formulation
DE10335027A1 (de) 2003-07-31 2005-02-17 Boehringer Ingelheim Pharma Gmbh & Co. Kg Verwendung von Angiotensin II Rezeptor Antagonisten
US20040229901A1 (en) * 2003-02-24 2004-11-18 Lauren Otsuki Method of treatment of disease using an adenosine A1 receptor antagonist
US20060293312A1 (en) * 2003-04-25 2006-12-28 Howard Dittrich Method of improved diuresis in individuals with impaired renal function
CA2522971A1 (en) * 2003-04-25 2004-11-11 Novacardia, Inc. Method of improved diuresis in individuals with impaired renal function
KR100473422B1 (ko) * 2003-06-12 2005-03-14 박원봉 렉틴 함유 천연물의 장용성 코팅용 조성물
CA2529746C (en) * 2003-06-16 2010-08-03 Andrx Pharmaceuticals, Llc Oral extended-release composition
US7198653B2 (en) 2003-07-31 2007-04-03 Delavau Llc Calcium carbonate granulation
US20050031683A1 (en) * 2003-08-04 2005-02-10 Ashish Kapoor Solid pharmaceutical composition
US7390503B1 (en) 2003-08-22 2008-06-24 Barr Laboratories, Inc. Ondansetron orally disintegrating tablets
US7282217B1 (en) * 2003-08-29 2007-10-16 Kv Pharmaceutical Company Rapidly disintegrable tablets
CA2536487C (en) * 2003-09-12 2011-10-25 Amgen Inc. Rapid dissolution formulation of a calcium receptor-active compound
CN1856296A (zh) * 2003-09-30 2006-11-01 阿库斯菲尔公司 可注射的、口服、或局部用缓释药物制剂
US20050203482A1 (en) * 2004-03-15 2005-09-15 Chinea Vanessa I. Pharmaceutical dispensing apparatus and method
US20070196471A1 (en) * 2004-04-02 2007-08-23 Thosar Shilpa S Micronized Eplerenone Compositions
US20050232957A1 (en) * 2004-04-14 2005-10-20 Katz Kenneth A Compositions and methods for moisturizing skin
AU2005237466A1 (en) * 2004-04-16 2005-11-10 Novacardia, Inc. Combination therapy comprising an adenosine A1 receptor antagonist and an aldosterone inhibitor
US8075910B2 (en) * 2004-05-20 2011-12-13 Pbm Pharmaceuticals, Inc. Oral compositions comprising edible oils and vitamins and/or minerals and methods for making oral compositions
US7846466B2 (en) * 2004-06-10 2010-12-07 Northwestern University Biodegradable scaffolds and uses thereof
US20060134212A1 (en) * 2004-09-02 2006-06-22 Forest Laboratories, Inc. Lercanidipine immediate release compositions
US20060165789A1 (en) * 2004-09-09 2006-07-27 Forest Laboratories, Inc. Lercanidipine modified release compositions
US20060165788A1 (en) * 2004-09-09 2006-07-27 Wattanaporn Abramowitz Lercanidipine pH dependent pulsatile release compositions
US8022053B2 (en) * 2004-11-02 2011-09-20 Bayer Schering Pharma Aktiengesellschaft Oral solid dosage forms containing a low dose of estradiol
JP4773456B2 (ja) * 2004-11-23 2011-09-14 ドン ファ ファーマシューティカル カンパニー リミテッド 生体利用率を向上させた経口用製剤
WO2006097342A1 (en) * 2005-03-17 2006-09-21 Synthon B.V. Process for making steroidal compounds
US20060252738A1 (en) * 2005-05-06 2006-11-09 Phero Tech Inc. Method for preparing and using water-based steroid pheromone compositions
EP1896074A4 (en) * 2005-05-25 2009-04-22 Liponex Inc PHARMACEUTICAL COMPOSITIONS FOR THE TREATMENT OR PREVENTION OF CORONARY ARTERY DISEASE
WO2007012960A1 (en) * 2005-07-29 2007-02-01 Glenmark Pharmaceuticals Limited Pharmaceutical compositions of eplerenone
US20070095705A1 (en) * 2005-10-31 2007-05-03 Legault Dennis X Array of packages
CA2965211C (en) * 2006-01-13 2020-06-30 Indiana University Research & Technology Corporation Type v collagen-related molecules for the treatment of lung disease involving autoimmunity to type v collagen _________________________________________
US20070184163A1 (en) * 2006-02-07 2007-08-09 International Flavors, & Fragrances Inc. Non-hygroscopic flavor particles
WO2007102169A1 (en) * 2006-03-08 2007-09-13 Jubilant Organosys Limited Extended release pharmaceutical formulation of venlafaxine and method of manufacturing the same
US20070248665A1 (en) * 2006-04-24 2007-10-25 Sherman Bernard C Compositions comprising co-precipitate of eplerenone and a water-soluble excipient
MX2008015253A (es) * 2006-05-31 2008-12-17 Vertex Pharma Formulaciones de liberacion controlada.
CN101466383A (zh) * 2006-06-16 2009-06-24 美国诺华卡迪亚公司 包含低频率投与aa1ra的肾功能延长改善
DE102006033723A1 (de) * 2006-07-21 2008-01-24 Bayer Technology Services Gmbh Formulierungen von Multikompartimenten-Granulaten für Wirkstoffe
EP2051696A2 (en) * 2006-08-18 2009-04-29 Morton Grove Pharmaceuticals, Inc. Stable liquid levetiracetam compositions and methods
US9138414B1 (en) 2006-09-15 2015-09-22 Delavau Llc Calcium supplement having enhanced absorption
JP2010513325A (ja) * 2006-12-21 2010-04-30 アルファファーム ピーティーワイ リミテッド 医薬組成物
AU2008209264B2 (en) * 2007-01-22 2014-11-27 Mylan Pharmaceuticals Ulc Pharmaceutical compositions comprising nebivolol or a nebivolol analogue
JP5284967B2 (ja) * 2007-02-01 2013-09-11 武田薬品工業株式会社 打錠障害を生じない錠剤製剤
US20090197900A1 (en) * 2007-03-29 2009-08-06 Howard Dittrich Methods of treating heart failure and renal dysfunction in individuals with an adenosine a1 receptor antagonist
WO2008121882A1 (en) * 2007-03-29 2008-10-09 Novacardia, Inc. Improved methods of administration of adenosine a1 receptor antagonists
US8372431B2 (en) 2007-10-26 2013-02-12 Bial-Portela & C.A., S.A. Pharmaceutical composition comprising licarbazepine acetate
WO2009114226A1 (en) * 2008-03-11 2009-09-17 Mallinckrodt Inc. Use of magnesium stearate dihydrate for lubrication of solid pharmaceutical compositions
WO2010014952A2 (en) * 2008-07-31 2010-02-04 Clarke Mosquito Control Products, Inc. Extended release tablet and method for making and using same
GB0814953D0 (en) * 2008-08-18 2008-09-24 Unilever Plc Improvements relating to nanodisperse compositions
US8545892B2 (en) 2009-06-26 2013-10-01 Nano Pharmaceutical Laboratories, Llc Sustained release beads and suspensions including the same for sustained delivery of active ingredients
TR201807532T4 (tr) * 2009-08-28 2018-06-21 Hercules Llc Katı toz bileşiklerinden ince tabaka kaplama bileşimi.
US9345848B2 (en) 2009-10-20 2016-05-24 Sima Patent Ve Lisanslama Hizmetleri Ltd. Sti. Dry powder inhaler
EP2633857B1 (en) 2009-12-23 2015-08-12 ratiopharm GmbH Solid pharmaceutical dosage form of ticagrelor and acetylsalicylic acid
US20120308652A1 (en) * 2009-12-23 2012-12-06 Daniela Stumm Oral form of administration comprising entecavir
JP5669837B2 (ja) * 2010-06-16 2015-02-18 帝人ファーマ株式会社 放出制御型の有核錠剤
TR201007653A2 (tr) * 2010-09-20 2012-04-24 Bi̇lgi̇ç Mahmut Eplerenon içeren farmasötik kompozisyon
KR20120093461A (ko) * 2011-01-27 2012-08-23 양지화학 주식회사 정제형 감미료 조성물 및 그 제조방법
WO2013095311A1 (en) 2011-11-25 2013-06-27 Mahmut Bilgic Inhalation device
EP2875359A4 (en) 2012-03-30 2015-08-19 Charles R Drew University Of Medicine And Science COMPOSITIONS AND METHODS FOR TREATING OR PREVENTING METABOLISM SYNDROME DISEASES
MX387669B (es) 2012-06-04 2025-03-18 Pharmacyclics Llc Formas cristalinas de un inhibidor de tirosina quinasa de bruton.
FR3001890B1 (fr) * 2013-02-08 2015-08-07 Greenpharma Sas Composition dermatologique pour repousse des poils ou des cheveux
US20140271923A1 (en) 2013-03-14 2014-09-18 Christopher Brian Reid Compositions & formulations for preventing and treating chronic diseases that cluster in patients such as cardiovascular disease, diabetes, obesity, polycystic ovary syndrome, hyperlipidemia and hypertension, as well as for preventing and treating other diseases and conditions
USD744087S1 (en) 2013-10-01 2015-11-24 Mahmut Bilgic Dry powder inhaler
US11007203B2 (en) * 2013-10-06 2021-05-18 Salim Shah Formulations comprising aldosterone receptor antagonists and treatments using same
EP3079697B1 (en) 2013-12-12 2021-02-03 Cornell University Prolylhydroxylase/atf4 inhibitors for treating neural cell injury
FR3019045A1 (fr) * 2014-03-26 2015-10-02 Greenpharma Sas Composition dermatologique pour la repousse des poils ou des cheveux
CA2955747A1 (en) 2014-08-07 2016-02-11 Pharmacyclics Llc Novel formulations of a bruton's tyrosine kinase inhibitor
WO2016063269A1 (en) 2014-10-20 2016-04-28 Prendergast Patrick T Use of antagonists to the nuclear steroid receptor alone or in combination as direct antiviral agents to inhibit alphavirus, togaviridae, arenaviridae, filoviridae, bunyaviridae, flaviviridae and rhabdoviridae
US9931344B2 (en) 2015-01-12 2018-04-03 Nano Pharmaceutical Laboratories, Llc Layered sustained-release microbeads and methods of making the same
IL315294A (en) 2015-03-03 2024-10-01 Pharmacyclics Llc Pharmaceutical formulations of bruton's tyrosine kinase inhibitor
GB201913972D0 (en) * 2019-09-27 2019-11-13 Univ Ulster Pharmaceutical Delivery Device and method of manufacture

Family Cites Families (22)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4082751A (en) * 1976-02-13 1978-04-04 Bristol-Myers Company Therapeutic agents
IT1130924B (it) * 1980-03-06 1986-06-18 Secifarma Spa Procedimento per la preparazione di spironolattone micronizzato
US4559332A (en) * 1983-04-13 1985-12-17 Ciba Geigy Corporation 20-Spiroxanes and analogues having an open ring E, processes for their manufacture, and pharmaceutical preparations thereof
US5082668A (en) 1983-05-11 1992-01-21 Alza Corporation Controlled-release system with constant pushing source
IE58110B1 (en) * 1984-10-30 1993-07-14 Elan Corp Plc Controlled release powder and process for its preparation
US4753802A (en) 1986-03-19 1988-06-28 Alza Corporation Verapamil dosage form
GB8613689D0 (en) * 1986-06-05 1986-07-09 Euro Celtique Sa Pharmaceutical composition
US4847093A (en) 1986-06-19 1989-07-11 Alza Corporation Dosage form with means for governing rate of gas formation
US5057317A (en) 1987-03-24 1991-10-15 Chugai Seiyaku Kabushiki Kaisha Slow-release pharmaceutical agent
GB8717168D0 (en) 1987-07-21 1987-08-26 Roussel Lab Ltd Controlled-release device
NZ238867A (en) 1990-07-12 1993-08-26 Alza Corp Dosage form for delayed release comprising pharmaceutically active substance and a drug-release hindering means and a second composition which imbibes fluid, expands, and ejects the active substance from the device
AU1432292A (en) 1991-02-07 1992-09-07 Lawrence Samuel Bass Drug delivery composition and method of using the same
US5190765A (en) 1991-06-27 1993-03-02 Alza Corporation Therapy delayed
US5160744A (en) 1991-06-27 1992-11-03 Alza Corporation Verapmil therapy
US5529992A (en) * 1992-04-21 1996-06-25 Curators Of The University Of Missouri Method for inhibiting myocardial fibrosis by administering an aldosterone antagonist which suppresses aldoster one receptors
IT1260505B (it) 1992-06-01 1996-04-09 Poli Ind Chimica Spa Sistemi farmaceutici orali a cessione ritardata per il rilascio specifico nel colon
US5324718A (en) * 1992-07-14 1994-06-28 Thorsteinn Loftsson Cyclodextrin/drug complexation
GB9311191D0 (en) 1993-05-29 1993-07-14 Danbiosyst Uk Controlled release drug formulation
AU5692398A (en) 1996-12-09 1998-07-03 Proscript, Inc. Substituted 5-amino-1,3,4-thiadiazole-2-thiones
ES2186017T3 (es) 1996-12-11 2003-05-01 Searle & Co Procedimientos para la preparacion de delta 4,5-esteroides 3-ceto-7alfa-alcoxicarbonil-sustituidos y compuestos intermedios de utilidad en los mismos.
UA74141C2 (uk) * 1998-12-09 2005-11-15 Дж.Д. Сірл Енд Ко. Фармацевтична композиція на основі тонкоподрібненого еплеренону (варіанти), спосіб її одержання та спосіб лікування розладів, опосередкованих альдостероном (варіанти)
PT1175220E (pt) * 1999-12-08 2005-07-29 Pharmacia Corp Composicoes de eplerenona em nanoparticulas

Also Published As

Publication number Publication date
IS2325B (is) 2007-12-15
ZA200104361B (en) 2002-05-28
US20020136775A1 (en) 2002-09-26
ES2207977T3 (es) 2004-06-01
KR100671275B1 (ko) 2007-01-19
NO20012782D0 (no) 2001-06-06
UA74141C2 (uk) 2005-11-15
KR20010101132A (ko) 2001-11-14
EA003266B1 (ru) 2003-02-27
US6495165B1 (en) 2002-12-17
HU224428B1 (hu) 2005-09-28
HK1041641B (zh) 2006-04-28
PT1135139E (pt) 2004-02-27
US6558707B1 (en) 2003-05-06
US7157101B2 (en) 2007-01-02
ID30115A (id) 2001-11-08
DK1135139T3 (da) 2004-01-05
US20030072808A1 (en) 2003-04-17
IS5953A (is) 2001-05-25
BR9915964A (pt) 2001-08-28
MY125651A (en) 2006-08-30
CN1230179C (zh) 2005-12-07
US20030215518A1 (en) 2003-11-20
NZ511869A (en) 2003-05-30
US6534093B1 (en) 2003-03-18
AU763166B2 (en) 2003-07-17
US6592902B2 (en) 2003-07-15
WO2000033847A1 (en) 2000-06-15
US6410054B1 (en) 2002-06-25
US6863902B2 (en) 2005-03-08
HUP0104718A2 (hu) 2003-01-01
HUP0104718A3 (en) 2002-10-28
EP1135139B1 (en) 2003-09-10
JP2002531508A (ja) 2002-09-24
EA200100519A1 (ru) 2002-02-28
NO20012782L (no) 2001-07-03
HK1041641A1 (en) 2002-07-19
CA2326842A1 (en) 2000-06-15
CN1329494A (zh) 2002-01-02
PL198425B1 (pl) 2008-06-30
AR028982A1 (es) 2003-06-04
TR200101643T2 (tr) 2002-04-22
CZ20011942A3 (cs) 2001-12-12
US20040192661A1 (en) 2004-09-30
EP1135139A1 (en) 2001-09-26
TWI234459B (en) 2005-06-21
DE69911240T2 (de) 2004-07-15
AU1936800A (en) 2000-06-26
ATE249223T1 (de) 2003-09-15
DE69911240D1 (de) 2003-10-16

Similar Documents

Publication Publication Date Title
IL143301A0 (en) Micronized eplerenone compositions
AP2000001874A0 (en) Cellecoxib compositions
GB9917982D0 (en) Compositions
PL347266A1 (en) Antiperspirant compositions
GB9811377D0 (en) Compositions
GB9924268D0 (en) Compositions
PL343627A1 (en) Medicinal compositions
GB9828861D0 (en) Compositions
GB9904049D0 (en) Rapidly-soluble compositions
GB9805782D0 (en) Compositions
GB2339693B (en) Anti-mollusc compositions
GB9827291D0 (en) Compositions
GB9812818D0 (en) Dentfrice compositions
GB9905746D0 (en) Compositions
GB9822158D0 (en) Compositions
GB2336535B (en) Compositions
GB9809347D0 (en) Compositions
GB9827690D0 (en) Compositions
GB9816050D0 (en) Compositions
GB9818278D0 (en) Compositions
GB9810307D0 (en) Compositions
GB9808595D0 (en) Compositions
GB9823750D0 (en) Compositions
GB9824922D0 (en) Odour-neutralising compositions
GB9824924D0 (en) Odour-neutralising compositions

Legal Events

Date Code Title Description
KB Patent renewed
MM9K Patent not in force due to non-payment of renewal fees